Neutral
Last updated: 2026-05-21 19:47:16 ET
The injection is different than Zepbound and Foundayo.
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.
People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.
Eli Lilly claims in a civil lawsuit that it's the victim of a $200 million plus drug rebate fraud tied to Pentecostal church bishops and businesses.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Earlier this week, Eli Lilly reported detailed late-phase obesity trial results showing long-term weight maintenance with injectable Zepbound and oral...
Picture a drug so popular that, even in markets where a cheaper generic competitor had just launched, it still grew by 10%. That's what happened to El...
Eli Lilly (LLY) stock is back in focus after the company reported a very strong Q1, raised its full year revenue and earnings guidance, and released n...
Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE